RocScholar (Rochester Regional Health)
Not a member yet
3788 research outputs found
Sort by
Ectopic pregnancy after hysterectomy study: A systematic review of published case reports comparing ectopic pregnancy following total and supracervical hysterectomy
No full textPurpose: To perform a systematic review of all published case reports and compare ectopic pregnancy following total versus supracervical hysterectomy.
Methods: Published case reports of patients with ectopic pregnancy following hysterectomy up to July 12, 2024, were searched using PubMed, Google Scholar, Embase, Scopus, and Web of Science databases using the terms post-hysterectomy ectopic pregnancy, OR pregnancy after hysterectomy. Manuscripts with case reports of ectopic pregnancy following previous hysterectomy were statistically analyzed. Categorical variables were analyzed using the chi-squared or Fisher\u27s exact test and continuous variables by independent t-test and Wilcoxon rank sum test. A p-value \u3c 0.05 determined statistical significance.
Main results: One hundred and eight cases reported by 106 authors were eligible for analysis. Of these, 34 underwent supracervical and 74 total hysterectomies. There were no differences between the two groups in the demographic variables, symptoms, and status of patients at presentation. Patients with a history of supracervical, unlike total hysterectomy, were less likely to have their pregnancy associated with the period just before or shortly after hysterectomy (termed the peri-hysterectomy period) (OR 0.18, 95% CI [0.06-0.54], p \u3c 0.001). However, they are more likely to have a diagnosis of possible ectopic pregnancy before surgery (OR 3.56, 95% CI [1.45-8.73], p = 0.007).
Conclusion: Physicians should be aware that ectopic pregnancy following a supracervical, unlike total hysterectomy, occurs more often remote from the peri-hysterectomy period and should include ectopic pregnancy in their differential diagnosis of abdominal and pelvic pain in all previously hysterectomized patients
RRH Library Newsletter, Spring 2025
Full text linkNewsletter sections include: Retirement Announcement: Tami Hartzell, MLS, Evidence-based Practice (CH); New Archives Section on Library Website; Medical Library Association Statement; 2025 Guideline Update
Two Interesting Cases of Left Ventricular Free Wall Rupture in Myocardial Infarction
No full textWe present two interesting cases of left ventricular free wall rupture following ST elevation myocardial infarction. First case was not identified on echocardiography and angiography despite high suspicion and later underwent emergent lifesaving mediastinal exploration and repair. Second case had a delayed presentation of inferior STEMI and cardiac tamponade. These cases highlight the diagnostic challenges and variable presentations of left ventricular free wall rupture (LVFWR)
S3012 Integrating Iterative Large Language Model Collaboration Into Complex Gastrointestinal Case Management: A Pilot Evaluation
No full textS6245 Concurrent Eosinophilic Esophagitis and Eosinophilic Gastroenteritis Presenting With Gastric Outlet Obstruction
No full text396P Accelerating postmenopausal breast cancer mortality in obese women in the united states: A 22-year nationwide analysis
No full textImproving Emergency Care Through Standardized Post Event Debriefing
No full texthttps://scholar.rochesterregional.org/nursingresearchday_2025/1009/thumbnail.jp
Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey
No full textBACKGROUND: Transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) is typically managed with induction therapy, high-dose chemotherapy consolidation, and subsequent maintenance therapy. This survey-based study explored real-world practices by evaluating how a patient\u27s cytogenetic risk stratification, physician\u27s institutional affiliation, sub-specialty, and years of experience influence the choice of regimens.
METHODS: From May to July 2024, a cross-sectional survey was conducted among US-based hematologists and oncologists, including plasma cell disorder specialists. The survey gathered data on induction, consolidation, and maintenance therapies for TE-NDMM patients with risk stratification based on cytogenetic profiles. Descriptive and inferential statistical analyses identified trends and associations between covariates.
RESULTS: The combination of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) was found to be the predominant induction regimen for high-risk (78%), standard-risk (63%), and fluorescence in situ hybridization (FISH)-status unavailable disease (73%). The most used regimens involved a weekly dose of subcutaneous bortezomib, a lower dose of dexamethasone, and lenalidomide 25 mg given in a 21/28-day cycle. Additionally, post-transplant lenalidomide monotherapy was the frequently used maintenance strategy. Minimal residual disease (MRD) assessment was underutilized among participants. Physician specialty influenced regimen selection, with plasma cell specialists favoring newer quadruplet therapies. Likewise, a physician\u27s institutional affiliation and years of practice further contributed to real-world practice variability.
CONCLUSIONS: Real-world practice patterns demonstrate antibody-based four-drug induction regimens as the preferred choice in TE-NDMM, highlighting evidence-based adoption. Doses were modified to optimize patient outcomes, efficacy, safety, and disease control. However, variability in post-transplant maintenance and underutilization of MRD assessment underscores the need for standardized guidelines
